Novel oral anticoagulants: an ENT surgeon’s pocket reference tool

Rate this item
(0 votes)


Introduction: Novel oral anti-coagulants (NOACs) are set to become increasingly common in ENT patients. January 2015 NICE guidelines recommend rivaroxaban for up to 1 year after a myocardial infarction. This review sets out a guide to managing the new anticoagulants in acute and elective ENT patients.

Methods: Medline/ EMBASE searches and reviews of specialist society guidelines and expert recommendations were conducted.

Results: Limited RCT evidence exists to date on peri-operative management and emergency reversal. We have therefore condensed society guidelines and expert recommendations to create a succinct, practical guide to the peri-operative and emergency management of these patients.

Conclusion: Novel anticoagulants are poised to take over from warfarin (at least 1% of the UK adult population) for most indications. Yet in practice most surgeons have had limited experience with them. This review and ‘surgeon’s guide’ aims to set out a best-evidence foundation from which to respond to the emerging challenge.

Additional Info

  • Authors: Y Kamhieh & H Fox
  • Keywords: novel oral anticoagulants – rivaroxaban – apixaban – dabigatran – peri-operative – elective surgery - emergency surgery – epistaxis – bleeding – haemorrhage
Read 12597 times Last modified on Tuesday, 24 October 2017 15:18

Leave a comment

Make sure you enter the (*) required information where indicated. HTML code is not allowed.


Member Login

          Forgot login? | Register

BBC News Feed

Get in touch

+44 207 637 3544

This email address is being protected from spambots. You need JavaScript enabled to view it.

The Otorhinolaryngologist,
73 Newman Street, London
W1T 3EJ, 


Rila Publications Ltd Ethics Policy